tirzepatide summit American Heart Association Scientific Sessions 2024 has started off with a bang! Results are in for the study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk 🔴Tirzepatide (Mounjaro) at a glance❤️🩺⤵️

Supplemental Table 2, Fig

Does constipation or diarrhea dominate on each medication

DVT is the most common cause of PE

Lilly could have put some solutions in place for people who had already started the drug. For now, she lives in uncertainty, with no guarantee that she will be able to access the medication again.

By month 4 or 5, most patients reach their therapeutic dose with minimal or no nausea, allowing them to focus on sustainable weight loss rather than side effect management

India is now the first major market where multiple semaglutide competitors have launched simultaneously - and the price benchmarks being set will shape the global GLP-1 landscape for years to come